皮质髓质期CT上的瘤周皮质低强化征:小肾脏恶性肿瘤的独特指标
回顾性分析三个机构595例患者603个≤4 cm小肾脏肿块(507恶性、96良性;409透明细胞肾细胞癌、194非透明细胞肾细胞癌)的薄层皮质髓质期CT,评估瘤周皮质低强化(PCLE)征的诊断价值。PCLE诊断恶性的敏感度64.3%、特异度94.8%,诊断透明细胞肾细胞癌的敏感度75.1%、特异度87.6%,≤3 cm肿瘤特异度更高;厚层CT队列结果与主队列接近。
要点
- PCLE征定义为皮质髓质期肿瘤-皮质交界处局灶性低强化区,类似早期暗皮质带征。
- PCLE诊断小肾脏肿块恶性的特异度94.8%,诊断透明细胞肾细胞癌的特异度87.6%。
- ≤3 cm肿瘤中PCLE诊断恶性特异度达100%,但敏感度有限,嗜酸细胞瘤可出现假阳性。
核心结论
- 皮质髓质期CT上的PCLE征对小肾脏肿块恶性和透明细胞肾细胞癌具有极高特异度,尤其在≤3 cm肿瘤中,但敏感度有限,嗜酸细胞瘤可出现假阳性。
研究设计与样本
- 回顾性分析三个机构595例患者603个经组织病理学证实的小肾脏肿块(≤4 cm),使用薄层CT(≤1.5 mm)评估PCLE征;另分析108例患者109个小肾脏肿块厚层CT(3 mm)队列,方法相同。
关键影像表现/征象
- PCLE征表现为皮质髓质期肿瘤-皮质交界处局灶性低强化区,类似早期暗皮质带征。
- 603个小肾脏肿块中331个(54.9%)检出PCLE征,包括326个恶性和5个良性(均为>3 cm的嗜酸细胞瘤),以及307个透明细胞肾细胞癌和24个非透明细胞肾细胞癌。
- 厚层CT队列结果与薄层CT主队列结果高度一致。
诊断标准与关键数值
- PCLE诊断恶性小肾脏肿块的敏感度64.3%(326/507)、特异度94.8%(91/96)。
- PCLE诊断透明细胞肾细胞癌的敏感度75.1%(307/409)、特异度87.6%(170/194)。
- ≤3 cm肿瘤中PCLE诊断恶性的特异度100%(78/78),诊断透明细胞肾细胞癌的特异度93.5%(129/138)。
- PCLE观察者间一致性为中等至高度(Cohen kappa 0.783)。
临床应用与阅片要点
- 在皮质髓质期CT上观察肿瘤-皮质交界处是否存在局灶性低强化区,有助于鉴别小肾脏肿块良恶性及透明细胞与非透明细胞肾细胞癌。
- PCLE征特异度高但敏感度有限,阴性不能排除恶性;嗜酸细胞瘤(尤其>3 cm)可出现假阳性。
- ≤3 cm肿瘤中PCLE征诊断恶性特异度达100%,对报告良恶性倾向有参考价值。
局限性
- 原文为回顾性研究。
- 排除了囊性变、可见脂肪、浸润性/完全内生/外生性生长模式的肿块。
- PCLE敏感度有限。
- 嗜酸细胞瘤可出现假阳性。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To retrospectively evaluate the diagnostic potential of the peritumoral cortex low-enhancement (PCLE) sign on corticomedullary phase (CMP) CT images for differentiating malignant from benign lesions and clear cell renal cell carcinoma (ccRCC) from non-ccRCC among small renal masses (SRMs, ≤4 cm).
MATERIALS AND METHODS: After excluding cases with incomplete/poor-quality CT images and SRMs exhibiting cystic changes, visible fat, or infiltrative/completely endophytic/exophytic growth patterns, 603 histopathologically confirmed SRMs (507 malignant and 96 benign; 409 ccRCC and 194 non-ccRCC) from 595 patients across three institutions were retrospectively analyzed using thin-slice CT images (≤1.5 mm). PCLE was defined as a focal low-enhancement region of the peritumoral cortex at the tumor-cortex interface on CMP CT images, similar to the early dark cortical band sign. Diagnostic performance of PCLE for malignancy and ccRCC was evaluated. A separate cohort of 109 SRMs (91 malignant and 18 benign; 77 ccRCCs and 32 non-ccRCCs) from 108 patients, imaged with thick-slice CT (3 mm), was additionally analyzed using otherwise the same methodology.
RESULTS: PCLE was identified in 331 SRMs (54.9%, 331/603), including 326 malignant and 5 benign SRMs (all oncocytomas >3 cm), and in 307 ccRCC and 24 non-ccRCC SRMs. For diagnosing malignant SRMs, PCLE demonstrated a sensitivity of 64.3% (326/507) and specificity of 94.8% (91/96). For ccRCCs, these values were 75.1% (307/409) and 87.6% (170/194), respectively. In tumors ≤3 cm, specificity reached 100% (78/78) for malignancies and 93.5% (129/138) for ccRCCs. Inter-observer agreement for PCLE was substantial (Cohen's kappa, 0.783). Findings from the thick-slice cohort closely mirrored those in the primary cohort obtained using thin-slice CT images.
CONCLUSION: PCLE observed on CMP CT demonstrated exceptional specificity for malignant and ccRCC among SRMs, especially in SRMs ≤3 cm, though sensitivity was limited, and false positives occurred in oncocytomas.
引用
- Qu J, Li X, Zhu P, et al. Peritumoral Cortex Low-Enhancement Sign on Corticomedullary Phase CT: A Distinctive Indicator of Small Renal Malignancies. Korean J Radiol. 2025. PMID: 41015858. doi:10.3348/kjr.2025.0458
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。